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      Chapter  4
In this thesis we have investigated pharmacokinetically based strate-
gies for optimization of aminoglycoside and vancomycin therapies. The 
current chapter will summarize and discuss the results of our studies 
investigating aminoglycoside and vancomycin pharmacokinetics in the 
studied patient populations with infections.
Once daily and extended interval dosing of aminoglycosides
As once daily dosing of aminoglycosides has gained popularity world-
wide, more data are available on once daily dosing regimens in various 
clinically infected populations. In the study described in Chapter 2.1 we 
focused on adult cystic fibrosis (CF) patients. CF patients are frequent-
ly exposed to high doses of once daily dosed (ODD) tobramycin with 
relatively long treatment course duration in case of pulmonary exacer-
bations (1). The tobramycin dosages range from 10 to 15 mg/kg once 
daily in this population. Based on harmacokinetic/pharmacodynamic 
(PK/PD) considerations a high dose per kg bodyweight is a consequen-
ce of the relatively large volume of distribution and high clearance in 
comparison to other clinically infected populations treated with aminog-
lycosides (2). Current once daily high tobramycin dosing protocols in 
pediatric and adult CF patient populations result in high peak and low 
trough concentrations ensuring efficacy and limiting the risk of toxicity, 
respectively (3). In Chapter 2.1 the influence of the time of adminis-
tration on the PK of tobramycin in adult CF patients was investigated. 
This study was designed to test the assumption that dosing in the 
evening results in a lower clearance and an increased area under the 
concentration-time curve (AUC) of aminoglycosides due to the circa-
dian rhythm of renal function. In close collaboration, the effect of the 
circadian rhythm on tobramycin PK was studied in pediatric CF patients 
by investigators at the University of Nottingham, UK. Results from the 
latter studies indicate no clinically relevant effect of the administration 
time on tobramycin PK in CF patients. In Chapter 2.2 we performed a 
retrospective cohort study that investigated the effect of the time of ad-
ministration of aminoglycosides in general ward patients and in intensi-
ve care unit (ICU) patients. In these clinically infected populations also 
no effects of the time of administration could be detected on the PK of 
aminoglycosides. Furthermore, the incidence of nephrotoxicity was not 
affected by the time of administration in the general ward population.
We suggest that the lack of an effect of the time of administration on 
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aminoglycoside PK in CF patients, general ward patients and ICU 
patients is caused by a distortion of the ‘normal’ circadian rhythm in 
these clinically infected patients. Previous reports have demonstrated 
that changes in immunological status affect the circadian rhythm, e.g. 
sepsis will abrogate the normal melatonin secretion over the day (4-6). 
The presence of a ‘normal’ circadian rhythm is influenced by distortion 
of immunological homeostasis. In fact, based on our observations we 
hypothesize that intravenous antibiotic agents will rarely show a diurnal 
pattern since they are prescribed to patients with serious suspected or 
proven infections. 
In Chapter 2.3 we investigated the PK and nephrotoxicity of ODD gen-
tamicin and ODD tobramycin in a large retrospective cohort of infected 
general ward patients. The most important finding of this study was a 
fifty percent lower incidence of nephrotoxicity in patients treated with to-
bramycin compared to those treated with gentamicin. To our knowledge 
no previous studies have compared the clinical toxicity of two or more 
ODD aminoglycosides. Importantly, this study offers a pharmacological 
explanation for the difference in nephrotoxicity between gentamicin and 
tobramycin, since the PK analysis showed that gentamicin clearance 
was lower than tobramycin clearance. As a consequence, gentamicin 
exposure in terms of daily AUC was higher compared to tobramycin 
exposure. Mechanistically, our findings can be explained by the higher 
renal accumulation of gentamicin versus tobramycin inducing renal in-
jury (7). Finally, a multivariate analysis showed that the AUC of the first 
administration was a strong predictor of the incidence of nephrotoxicity 
indicating ‘early therapeutic drug monitoring (TDM)’ using limited AUC 
sampling can be of additive value identifying those patients at risk and 
therefore is of clinical relevance. 
In Chapter 2.4 we prospectively evaluated a gentamicin dosing regi-
men which is used in newborns with suspected or proven neonatal 
sepsis. This study showed that a dosing regimen of 5 mg/kg every 36h 
resulted in therapeutic exposure of over 90% of included subjects. It is 
important to note that this study was not performed in a neonatal inten-
sive care unit (NICU) but in a level 2 special care nursery population. 
In accordance with previous reports (8), we found a strong relationship 
between the volume of distribution (L/kg) of gentamicin with body-
weight in our population, with a larger bodyweight-corrected volume of 
distribution in preterm infants due to differences in body composition. 
Gentamicin half-life decreased with lower gestational age, which has 
also been reported by others (9). A combination of low weight-corrected 
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volume of distributions with short half-lives will translate in concentra-
tion-vs-time-curves with high peak concentrations and steep slopes. 
Vice versa, in low-birth-weight premature newborns peak concentrati-
ons and half-lives were lower and longer, respectively. Interestingly, the 
AUC was not related to gestational age or body weight, meaning that 
using the proposed dosing regimen in low birth-weight more premature 
newborns on average had the same gentamicin exposure compared to 
older neonates with higher bodyweights.
Continuous infusion of vancomycin
In Chapter 3.1 we performed a review of the literature comparing the 
inter-patient exposure variability in clinically infected patients on conti-
nuous or intermittent infusion of vancomycin. This review showed that 
continuous infusion conferred a fifty percent lower inter-patient variabili-
ty of vancomycin concentrations compared to intermittent infusion. This 
interesting finding based on the review of in total 34 published reports 
led to the design of a retrospective cohort study in an ICU population 
(Chapter 3.2). In this study we confirmed the hypothesis that the in-
ter-patient variability in vancomycin exposure was significantly lower for 
continuously dosed versus the intermittently dosed critically ill patients. 
Furthermore, ‘plateau’ concentrations in continuous dosing showed a 
stronger correlation with estimated AUCs compared to trough concen-
trations during intermittent dosing. Two conveyable causes can largely 
explain the reported results in Chapter 3.1 and 3.2. First, since ‘trough 
sample timing’ can have a major influence on the measured vancomy-
cin concentrations, an intermittent dosing regimen monitored by trough 
concentration is inherently prone to higher variability in comparison to 
continuous infusion and ‘plateau’ concentration monitoring (10). 
Second, when trough concentrations are monitored in case of intermit-
tent dosing the variability of the AUC is not only affected by the 
vancomycin clearance, but also by the volume of distribution (Chapter 
3.1 and 3.2). Patients with a relatively high volume of distribution will 
need higher intermittent dosages to maintain trough concentrations 
within the therapeutic range resulting in a large ‘delta’ between peak 
and trough concentrations and therefore in high AUCs, especially in 
once or twice daily dosing regimens. In Chapter 3.3 a simple method 
was presented to clinically implement a vancomycin continuous dosing 
nomogram based on historical within-population data obtained from 
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intermittently dosed patients. This chapter offers tools for clinicians 
considering a switch from intermittent to continuous dosing of vanco-
mycin. Although not intended for use in other clinically infected popula-
tions the developed dosing nomogram was in accordance with the only 
other prospectively validated dosing algorithm (11). 
Implications for clinical practice
In chapters 2.1 and 2.2 we showed that the time of administration did 
not affect the clearance or exposure in terms of AUC in CF patients, 
general ward patients and ICU patients. Hence, swifting administration 
times to the morning period is not recommended and 24 hour intervals 
should be maintained unless therapeutic drug monitoring results indi-
cate that the dosing interval needs to be extended (12). Furthermore, 
since early initiation of antibiotic treatment is paramount to improve out-
comes, the first administration of an aminoglycoside should take place 
as soon as possible after the diagnosis (13). 
Although our findings deserve to be confirmed, results from Chapter 
2.3 show a higher nephrotoxic potential of ODD gentamicin over ODD 
tobramycin in clinically infected patients treated for at least 3 days 
which may lead to the revision of (inter)national and local treatment 
protocols. In patients who are at high risk of developing nephrotoxicity 
and/or are likely to be treated over a longer period, tobramycin should 
be preferred over gentamicin. In fact, European cystic fibrosis treat-
ment guidelines already advocate to choose tobramycin over gentami-
cin for this reason (14, 15). The same concerns with regard to cumu-
lative toxicity apply to other highly exposed populations, e.g. patients 
treated for endocarditis. In order to optimize treatment with aminogly-
cosides ‘early’ AUC monitoring in addition to ‘trough levels’ should be 
implemented in daily routine, since our data suggest the AUC of the 
first administration is a strong predictor of nephrotoxicity. 
The added value to the present literature of our study results presented 
in Chapter 2.4 on gentamicin dosing in neonates lies in the specific 
neonatal population investigated. Current dosing regimens in neonates 
are largely based on data obtained from neonates admitted to a NICU 
(9, 16, 17), while the number of neonates exposed to gentamicin is 
likely to be higher in level 2 special care nurseries. Albeit our data de-
serve to be prospectively confirmed in a second independent cohort of 
neonates admitted to a level 2 special care nursery, our findings show 
that a more uniform dosing protocol of 5 mg/kg per 36 hours can be 
implemented in level 2 unit compared to more complex dosing proto-
cols proposed in neonates admitted to a level 3 intensive care unit (16, 
18, 19). As described in Chapter 3.1 vancomycin continuous dosing 
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protocols are rapidly gaining interest and are being implemented in 
clinical practice. Apart from some practical advantages over intermittent 
infusion, continuous infusion of vancomycin shows a more predictable 
exposure and thus the odds of an optimal target attainment as shown 
in Chapter 3.1 and 3.2 are better. In addition, continuous infusion of 
vancomycin might also be preferred since the drug preparation time, 
the staff workload and costs are reduced and it may also shorten 
hospital length of stay.(20, 21), (22) and has shown to be safe concern-
ing stability (23). Of course, there are also potential disadvantages to 
continuous infusion. Sufficient numbers of volume controlled infusion 
pump systems have to be secured and compatibility with other simul-
taneously infused drugs can be an issue. Nevertheless, ‘Y-site’-com-
patibility of vancomycin with many drugs has been demonstrated (24). 
Finally, based on our methodology described in Chapter 3.2 a ‘tailored’ 
dosing algorithm of vancomycin can be designed for clinically infected 
populations aiming to achieve a priori target exposure using historical 
within-population data, a PK model and PK software.
Suggestions for future studies
Toxicity studies in populations treated with ‘traditional’ dosing regi-
mens of aminoglycosides or vancomycin have been performed in the 
past. However, limited data are available on the recommended dosing 
regimens from most recent guidelines with respect to clinical outco-
mes (25, 26). For example, the most recent treatment guidelines for 
the treatment of multi-resistant S. aureus (MRSA) of the Infectious 
Diseases Society of America (IDSA) promoting high exposure targets 
for vancomycin are sparsely supported by safety data (27). Moreover, 
most toxicity studies on aminoglycosides were performed in the mul-
tiple daily dosing era. Therefore, prospective studies investigating the 
toxicity of currently prescribed once daily or extended-interval dosed 
aminoglycosides in highly exposed populations e.g. patients suffering 
from endocarditis are warranted. Newly developed high dosing proto-
cols of vancomycin for long-term MRSA treatment also raise questions 
about the risk/benefit ratio (28). 
Furthermore, there is a need for pharmacokinetic studies investiga-
ting vancomycin exposure in patients on continuous infusion in detail 
during the first 24 hours of therapy (29-31). Therefore, we advocate 
future studies to address this issue first by incorporating intensive 
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PK monitoring during the first 24 hours to design proper PK models 
of continuous infusion of vancomycin and identify optimal sampling 
times for limited sampling strategies in clinically infected populations. 
Secondly, determinants for patients at risk of under- or overexposure 
may be identified. Next, we recommend the implementation of ‘early 
TDM’, which has recently also been suggested for intermittent dosing 
of vancomycin (32). The AUC24h and steady state concentation can 
be estimated accurately shortly after initiation of vancomycin from two 
serum samples drawn within 12 hours after initiation of therapy using a 
validated PK model and PK software. This ‘early TDM’ approach offers 
the opportunity to swiftly identify patients that are or will be significantly 
under- or overexposed and may thereby enable clinicians to improve 
patient outcomes. Finally, the ongong debate on the preferential mode 
of administration of vancomycin should be addressed by large multi-
center investigations preferably of prospective randomized design.
Many experts believe that clinical usage of tobramycin and gentamicin 
will increase due to resistance to our current first line antibiotic arma-
mentarium (33-36). This could result in selection pressure of first choi-
ce aminoglycosides on a global scale. Recently, the Swedish Referen-
ce Group for Antibiotics (SRGA) has carried out a risk-benefit analysis 
of aminoglycoside treatment based on clinical efficacy, antibacterial 
spectrum, and synergistic effect with beta-lactam antibiotics, endotoxin 
release, toxicity, and side effects.  For instance, in cases of suspected 
infection caused by multidrug-resistant Enterobacteriaceae the SRGA 
nowadays promotes amikacin instead of gentamicin or tobramycin 
which is generally more active against extended-spectrum beta-lacta-
mase (ESBL)-producing and quinolone-resistant Escherichia coli than 
other aminoglycosides (37). 
Of interest, after the introduction of the SRGA guidelines the increase 
in Swedish orders of amikacin immediately lead to drug shortages in 
other EU countries. This is just one examples showing that antimicro-
bial agent shortages are of global concern and not limited to second or 
third world countries nowadays (38). It is a multifactorial problem and 
the current situation of antibiotic shortages is unfortunately more likely 
to aggravate than to disappear in the years to come. 
With regard to the amikacin nephrotoxic and ototoxic potential, there is 
mechanistic and clinical evidence that the risk of developing nephro-
toxicity is relatively low compared to the others within-class drugs (39, 
40). Nevertheless, more studies on amikacin with current once daily 
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dosing regimens are needed. For similar reasons, netelmicin, a previ-
ously used aminoglycoside which is though to have a low nephrotoxic 
potential (40, 41), will regain interest. It is also worthwhile to mention 
plazomicin, a promising aminoglycoside, that has been tested in phase 
3 studies (42). Plazomicin is designed to overcome tobramycin and 
gentamicin resistance. Human studies to date have not yet reported 
nephrotoxicity or ototoxicity, but lack of plazomicin ototoxicity has been 
reported in the guinea pig model for plazomicin (42). Given the repor-
ted increase in bacterial resistance to current antimicrobial agents, 
plazomicin may be considered a welcome addition to the antibacterial 
armamentarium pending positive results from large-scale clinical trials 
and other required clinical studies. In conclusion PK/PD studies of 
‘new’ dosing regimens of ‘older’ aminoglycoside antibiotics are urgently 
needed, anticipating broad clinical use of these antimicrobal agents in 
patient populations with serious infections and a high drug exposure.
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